We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Test Being Developed to Diagnose Mild Cognitive Impairment

By LabMedica International staff writers
Posted on 18 Feb 2013
Print article
Autoantibody biomarkers in the blood can potentially be used to diagnose early stages of Alzheimer's and Parkinson's diseases.

A grant of USD 799,800 from the Osteopathic Heritage Foundation at the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine (Stratford, NJ, USA) will help expand earlier research conducted by Robert Nagele, PhD, director of the Biomarker Discovery Center (at the University). Dr. Nagele's published research includes recent findings that identify specific autoantibody biomarkers in the blood for early diagnosis of Alzheimer's and Parkinson's diseases.

The funded project will pursue three specific goals: to identify a small number of autoantibody biomarkers that can accurately (90% or higher) diagnose MCI cases caused by early stage Alzheimer's disease; to verify the accuracy rate with a larger scale study; and to construct and test a diagnostic kit that is maximally accurate for the broadest possible MCI patient population. If successful, the study will then apply for final US Food and Drug Administration (FDA; Silver Spring, MD, USA) approval of the test.

"Using our novel biomarker discovery strategy, we have shown that it is possible to use a single drop of blood to diagnose Alzheimer's and Parkinson's with greater than 95% accuracy," said Dr Nagele. "This same approach should also allow us to identify a small number of biomarkers that can also accurately diagnose MCI caused by early-stage Alzheimer's disease."

Current approaches to MCI diagnosis rely on physical, neurological, and psychiatric examinations, laboratory tests, and a thorough review of the patient's medications and medical history. Recently, great attention has been given to using neuroimaging technologies to detect structural changes in the brain before symptoms appear. However, these approaches require expensive equipment and technology and can require hospital visits, the injection of radioactive compounds, and the availability of radiologists with advanced training in these techniques.

While current treatments for Alzheimer's cannot stop the progression of the disease, several medications are capable of significantly enhancing brain performance and alleviating symptoms. A number of promising drugs are also currently under development and in clinical trials for the treatment of early Alzheimer's disease. An easy-to-administer blood test for MCI would give pharmaceutical companies a way to identify patients for clinical trials who are at a very early stage of their disease and give researchers a nearly immediate way to monitor the effectiveness of medications under examination.

Related Links:

University of Medicine and Dentistry of New Jersey
US Food and Drug Administration


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.